Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2504MR)

This product GTTS-WQ2504MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2504MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12763MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ8736MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4944MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ13483MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ8305MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ655MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ434MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ1874MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW